Breaking News Instant updates and real-time market news.

IHRT

iHeartMedia

$14.51

-0.49 (-3.27%)

, SFIX

Stitch Fix

$21.01

-0.2 (-0.94%)

10:19
10/15/19
10/15
10:19
10/15/19
10:19

Fly Intel: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. iHeartMedia (IHRT) initiated with a Neutral at Goldman Sachs. 2. Stitch Fix (SFIX) initiated with an Outperform at Baird. 3. eHealth (EHTH) initiated with an Outperform at Raymond James. 4. Drive Shack (DS) initiated with an Outperform at JMP Securities. 5. Amarin (AMRN) initiated with a Neutral at Goldman amid 'bullish' consensus expectations. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

IHRT

iHeartMedia

$14.51

-0.49 (-3.27%)

SFIX

Stitch Fix

$21.01

-0.2 (-0.94%)

EHTH

eHealth

$55.75

2.63 (4.95%)

DS

Drive Shack

$4.01

0.28 (7.51%)

AMRN

Amarin

$15.56

0.12 (0.78%)

  • 22

    Oct

  • 24

    Oct

  • 07

    Nov

  • 14

    Nov

  • 28

    Dec

IHRT iHeartMedia
$14.51

-0.49 (-3.27%)

09/19/19
WOLF
09/19/19
INITIATION
Target $20
WOLF
Outperform
iHeartMedia initiated with an Outperform at Wolfe Research
Wolfe Research initiated iHeartMedia with an Outperform rating and $20 price target, calling it the only audio company past its heavy investment spending phase and ready to monetize its assets.
09/19/19
09/19/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Beyond Meat (BYND) initiated with an Overweight at Barclays. 2. Dave & Buster's (PLAY) initiated with a Hold at Stifel. 3. iHeartMedia (IHRT) initiated with a Neutral at B. Riley FBR. 4. PRA Health (PRAH) initiated with a Buy at Goldman Sachs. 5. Viper Energy (VNOM) initiated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/23/19
WELS
09/23/19
INITIATION
Target $21
WELS
Outperform
iHeartMedia initiated with an Outperform at Wells Fargo
Wells Fargo analyst Steven Cahall started iHeartMedia with an Outperform rating and $21 price target. The analyst likes the company's combination of assets, which he says "spans the linear-to-digital divide." He believes radio station reach gives iHeartMedia a strategic advantage in national ad campaigns, steady cash flow from syndicated content, and a "nicely sized" Events portfolio.
10/15/19
GSCO
10/15/19
INITIATION
Target $15
GSCO
Neutral
iHeartMedia initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Drew Borst initiated coverage of iHeartMedia with a Neutral rating and $15 price target. At current share levels, the positives of the company's emerging digital growth opportunity and EBITDA margin expansion are largely offset by negatives relating to cyclical risks to advertising and rising competitive intensity from audio streamers, Borst tells investors in a research note.
SFIX Stitch Fix
$21.01

-0.2 (-0.94%)

10/15/19
BARD
10/15/19
INITIATION
Target $28
BARD
Outperform
Stitch Fix started with Outperform, risk/reward attractive says Baird
Baird analyst Mark Altschwagger initiated coverage of Stitch Fix with an Outperform rating and $28 price target. Altschwager said the company offers a highly differentiated shopping experience, capable of capturing increased share of a highly fragmented apparel & accessories market. He said the future looks bright and the risk/reward is attractive.
10/14/19
BARD
10/14/19
INITIATION
Target $28
BARD
Outperform
Stitch Fix initiated with an Outperform at Baird
Baird analyst Mark Altschwagger initiated coverage of Stitch Fix with an Outperform rating and $28 price target.
10/08/19
STFL
10/08/19
NO CHANGE
Target $28
STFL
Buy
Stifel maintains favorable view of Stitch Fix after 'better than feared' Q4
Stifel analyst Scott Devitt said that despite the fact that some investors have expressed concerns over Stitch Fix's Q1 and FY20 profitability guidance, he thinks the company's Q4 results were "better than feared," he believes the company is right to invest to expand the platform and enhance the user experience and he sees a number of tailwinds for its longer-term growth. Devitt reiterated his Buy rating and $28 price target on Stitch Fix shares.
10/02/19
WELS
10/02/19
NO CHANGE
Target $20
WELS
Market Perform
Stitch Fix price target lowered to $20 from $30 at Wells Fargo
Wells Fargo analyst Ike Boruchow lowered his price target for Stitch Fix to $20 from $30 following "somewhat disappointing" Q4 results. More importantly, while top-line guidance continues to call for 20%-plus growth, the outlook for profitability is more concerning, he contends. The analyst reiterates a Market Perform rating on the shares.
EHTH eHealth
$55.75

2.63 (4.95%)

10/14/19
RAJA
10/14/19
INITIATION
Target $90
RAJA
Outperform
eHealth initiated with an Outperform at Raymond James
Raymond James analyst Gregory Peters initiated coverage of eHealth with an Outperform rating and $90 price target.
10/14/19
RBCM
10/14/19
NO CHANGE
RBCM
Outperform
eHealth churn concerns overdone, says RBC Capital
RBC Capital analyst Frank Morgan said he has been fielding an increasing number of in-bound calls on eHealth, whose shares are down nearly 50% in the last two months despite a lack of "any fundamental news." He thinks the selloff can be attributed to uncertainties around the election and Medicare-For-All rhetoric, as well as rotation out of momentum and high-growth names. He is hearing "concern and confusion" over policy churn and the impact on eHealth's constrained lifetime value metric, though Morgan said these are not new issues and he contends that "policy churn itself is not a bad thing." Along with the company's Q3 earnings release, which has been confirmed for Oct. 24, Morgan expects an update on performance to date for the 2020 annual enrollment period that starts on Oct. 15, which he thinks could lead to a turn in the stock. Morgan keeps an Outperform rating on eHealth shares.
10/04/19
RBCM
10/04/19
NO CHANGE
RBCM
Outperform
New healthcare executive order could be positive for eHealth, says RBC Capital
RBC Capital analyst Frank Morgan said President Trump's newly signed executive order on healthcare, dubbed "Protecting and Improving Medicare for Our Nation's Seniors," could provide an incremental long-term tailwind for eHealth's Medicare Advantage growth, assuming the administration's efforts gain traction. Morgan keeps an Outperform rating on eHealth shares.
10/14/19
RAJA
10/14/19
INITIATION
Target $90
RAJA
Outperform
eHealth initiated with an Outperform at Raymond James
Raymond James analyst Gregory Peters initiated coverage of eHealth with an Outperform rating and $90 price target. The analyst notes that the stock is down 50% from its 52-week high mainly because of concerns regarding potential versions of Democrat-sponsored Medicare-for-all programs, lower monthly Medicare Advantage - or MA - premiums, and a high level of churn from its customers enrolled during Q4 of 2018. Peters believes however that while the prospect of a Democrat administration may "bureaucratize" the MA market that is growing in popularity, the company represents a "pure play in the ongoing structural shift within the Medicare market" where demand continues to increase.
DS Drive Shack
$4.01

0.28 (7.51%)

10/15/19
JMPS
10/15/19
INITIATION
JMPS
Outperform
Drive Shack initiated with an Outperform at JMP Securities
10/15/19
JMPS
10/15/19
INITIATION
Target $8
JMPS
Outperform
Drive Shack initiated with an Outperform at JMP Securities
JMP Securities analyst Aaron Hecht initiated coverage of Drive Shack with an Outperform rating and $8 price target. The analyst believes that investor sentiment will "flip" on this "discounted" stock thanks to the progress being made under new management to generate "strong foot traffic". Hecht notes that Drive Shack has limited competition and strong economics, with the company also set to open 13 Drive Shack locations that will represent the "core" of its Entertainment Golf business. The analyst estimates the unleveraged Return on Invested Capital on the locations to be 16%-17%.
03/18/19
03/18/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Okta (OKTA) upgraded to Buy from Neutral at Goldman Sachs with analyst Heather Bellini saying the company's "strong" results since its April 2017 initial public offering continue to demonstrate the growing role that identity is playing in the wider enterprise information technology ecosystem. 2. Dollar General (DG) upgraded to Overweight from Equal Weight at Barclays with analyst Karen Short saying the company is doing what all "best-in-class" retailers do, it is investing from a position of strength to enhance its competitive edge, even if it means near-term guidance disappoints. 3. Johnson Controls (JCI) upgraded to Outperform from Market Perform at Wells Fargo with the firm's analyst saying the timing is now better for the story to play out. 4. Drive Shack (DS) upgraded to Outperform from In-Line at Imperial Capital with analyst George Kelly saying he is optimistic that the company's new venues opening this summer and fall will perform better than Orlando, and longer-term, he believe Drive Shack's management will be able to "navigate the rapidly growing golf entertainment space." 5. Dentsply Sirona (XRAY) upgraded to Outperform from Market Perform at William Blair with analyst John Kreger citing what he viewed as a positive International Dental Show. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/18/19
IMPC
03/18/19
UPGRADE
Target $7
IMPC
Outperform
Drive Shack upgraded to Outperform from In-Line at Imperial Capital
Imperial Capital analyst George Kelly upgraded Drive Shack to Outperform from In-Line and raised his price target for the shares to $7 from $5. The analyst is optimistic that the company's new venues opening this summer and fall will perform better than Orlando, and longer-term, he believe Drive Shack's management will be able to "navigate the rapidly growing golf entertainment space." The stock is attractive given the many "hidden" balance sheet assets and "big" growth opportunity, Kelly tells investors in a research note.
AMRN Amarin
$15.56

0.12 (0.78%)

10/15/19
GSCO
10/15/19
INITIATION
Target $17
GSCO
Neutral
Goldman starts Amarin at Neutral amid 'bullish' consensus expectations
Goldman Sachs analyst Paul Choi initiated coverage of Amarin with a Neutral rating and 12-month price target of $17. The shares closed Monday up 23c to $15.45. The Street's "bullish" forecasts "necessitate near-perfect commercial execution," Choi tells investors in a research note. Pending FDA approval, Amarin is poised to start promoting Vascepa, which is already approved for patients with hypertriglyceridemia, with an expanded label in a much broader population, which could drive "significant" sales growth over the next several years, contends the analyst. However, he believes that consensus expectations have set a high bar for initial uptake relative to prior cardiovascular launches. This could limit share outperformance over the next 12 months, says Choi.
08/15/19
CANT
08/15/19
NO CHANGE
Target $35
CANT
Overweight
Amarin panel not due to negative found by FDA, says Cantor Fitzgerald
The panel meeting for Amarin's Vascepa is not being held because the FDA found something negative in its review, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Rather, the analyst thinks the FDA may be hosting an AdCom for Vascepa "because the drug will be used in a very large patient population." Further, Amarin has been preparing, and continues to prepare, for the panel, Chen contends. In addition, she cautions against reading the tea leaves on the FDA's assignment and cancellation of AdCom meetings based on some historical examples. The analyst reiterates an Overweight rating on Amarin with a $35 price target. Chen still thinks the peak sales potential of Vascepa is underappreciated at current share levels. The stock closed yesterday up 53c to $14.82.
09/09/19
SBSH
09/09/19
NO CHANGE
SBSH
Buy
Now an attractive time to buy Amarin shares, says Citi
Citi analyst Joel Beatty continues to believe Amarin's Vascepa will likely be granted a cardiovascular risk reduction label shortly after the FDA panel meeting scheduled for November. This makes now an attractive time to buy the stock, Beatty tells investors in a research note. During a recent fireside chat, Amarin CEO John Thero highlighted two major upcoming sales inflection points, says the analyst. The first is the promotion of an expanded CV risk reduction label and the second is direct-to-consumer marketing, which the company expects to be able to begin six months after a label expansion, Beatty points out. The analyst believes this is likely to be a "powerful tool for patent education and physician education." He keeps a Buy rating on Amarin.
09/17/19
SBSH
09/17/19
NO CHANGE
SBSH
Citi puts Amarin and Sarepta on top five SMid cap biotech pick list
Citi analyst Joel Beatty removed The Medicines Co. (MDCO) and Minerva (NERV) from his top five Buy-rated stocks in SMid cap Biotech. These stocks are up 34% and 28%, respectively, since the analyst established them as among his top five Buy-rated stocks in July. Beatty replaced The Medicines Co. and Minerva with Amarin (AMRN) and Sarepta Therapeutics (SRPT). His top five buys are now Amarin, Eloxx Pharmaceuticals (ELOX), NGM Biopharmaceuticals (NGM), PTC Therapeutics (PTCT) and Sarepta. He wants to own Amarin into the November FDA panelmeeting, believing it will be "innocuous" and lead to a risk reduction label for Vascepa. On Sarepta, Beatty thinks the recent share pullback is overblown, and he reiterates his thesis that "although there will likely be some minor bumps on the road," the company will ultimately win the Image result for Duchenne muscular dystrophy gene therapy race

TODAY'S FREE FLY STORIES

CWK

Cushman & Wakefield

$19.10

0.1 (0.53%)

17:48
11/15/19
11/15
17:48
11/15/19
17:48
Hot Stocks
Cushman & Wakefield CEO sells 84.6K share of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LMT

Lockheed Martin

$393.52

3.305 (0.85%)

17:39
11/15/19
11/15
17:39
11/15/19
17:39
Hot Stocks
Lockheed Martin awarded maximum $3.33B Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESCA

Escalade

$10.90

-0.09 (-0.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Escalade CEO Fetherman to retire »

Escalade announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.96

0.1 (0.78%)

, ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Eldorado, Caesars stockholders approve Eldorado acquisition of Caesars »

Eldorado Resorts (ERI)…

CZR

Caesars

$12.96

0.1 (0.78%)

ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EGRX

Eagle Pharmaceuticals

$57.24

0.55 (0.97%)

17:15
11/15/19
11/15
17:15
11/15/19
17:15
Syndicate
Breaking Syndicate news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$60.82

0.84 (1.40%)

17:11
11/15/19
11/15
17:11
11/15/19
17:11
Hot Stocks
Fabrinet President Gill sells 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TEUM

Pareteum

$0.38

-0.0209 (-5.21%)

17:05
11/15/19
11/15
17:05
11/15/19
17:05
Hot Stocks
Pareteum receives noncompliance notice from Nasdaq »

Pareteum announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEXO

Hexo

$1.78

-0.1 (-5.32%)

17:00
11/15/19
11/15
17:00
11/15/19
17:00
Hot Stocks
Hexo was cannabis was being grown in unlicensed space at Niagara site »

HEXO Corp provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$220.84

2.29 (1.05%)

, CELG

Celgene

$110.02

-0.01 (-0.01%)

16:57
11/15/19
11/15
16:57
11/15/19
16:57
Hot Stocks
Bristol-Myers gets FTC clearance for Celgene acquisition »

Bristol-Myers Squibb…

AMGN

Amgen

$220.84

2.29 (1.05%)

CELG

Celgene

$110.02

-0.01 (-0.01%)

BMY

Bristol-Myers

$58.61

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

RAVE

Rave Restaurant

$1.44

-0.79 (-35.43%)

16:47
11/15/19
11/15
16:47
11/15/19
16:47
Hot Stocks
BBRC Asset Management reports 6.6% passive stake in Rave Restaurant »

BBRC Asset Management …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHAP

Chaparral Energy

$0.89

-0.0521 (-5.52%)

16:46
11/15/19
11/15
16:46
11/15/19
16:46
Hot Stocks
Chaparral Energy receives continued listing standard notice from NYSE »

Chaparral Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

CI

Cigna

$196.08

6.41 (3.38%)

, CNC

Centene

$57.57

2.91 (5.32%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks closed out the…

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

NVDA

Nvidia

$204.12

-5.76 (-2.74%)

AMZN

Amazon.com

$1,739.33

-15.38 (-0.88%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

UAA

Under Armour

$17.78

0.65 (3.79%)

UA

Under Armour

$15.97

0.41 (2.64%)

AMRN

Amarin

$23.99

2.5 (11.63%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

GOOG

Alphabet

$1,334.01

21.82 (1.66%)

GOOGL

Alphabet Class A

$1,333.33

23.54 (1.80%)

ORCL

Oracle

$56.43

0.33 (0.59%)

RH

RH

$188.73

13.535 (7.73%)

QGEN

Qiagen

$40.56

3.255 (8.73%)

FTCH

Farfetch

$9.66

2.17 (28.97%)

THC

Tenet

$30.55

1.08 (3.66%)

TORC

resTORbio

$1.10

-6.83 (-86.13%)

ACB

Aurora Cannabis

$2.72

-0.57 (-17.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 28

    Dec

  • 06

    Jan

  • 21

    Jan

  • 06

    Feb

NYT

New York Times

$31.60

0.44 (1.41%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
New York Times CEO sells 66,000 class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WEX

Wex

$200.52

4.61 (2.35%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
Wex director Morris sells 3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBLI

Cleveland BioLabs

$0.59

-0.0444 (-6.97%)

16:39
11/15/19
11/15
16:39
11/15/19
16:39
Hot Stocks
Cleveland BioLabs CEO resigns effective December 13th »

In a regulatory 8-K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGC

LogicBio Therapeutics

$9.29

-0.04 (-0.43%)

16:38
11/15/19
11/15
16:38
11/15/19
16:38
Syndicate
Breaking Syndicate news story on LogicBio Therapeutics »

LogicBio Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTBI

HomeTrust

$25.99

-0.31 (-1.18%)

16:38
11/15/19
11/15
16:38
11/15/19
16:38
Hot Stocks
HomeTrust raises quarterly dividend 17% to 7c per share »

HomeTrust Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

FR

First Industrial Realty

$42.05

-0.03 (-0.07%)

16:36
11/15/19
11/15
16:36
11/15/19
16:36
Hot Stocks
First Industrial Realty director sells 12K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSI

United Bankshares

$39.51

-0.19 (-0.48%)

16:31
11/15/19
11/15
16:31
11/15/19
16:31
Hot Stocks
United Bankshares declares Q4 dividend of 35c per share »

United Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
11/15/19
11/15
16:30
11/15/19
16:30
Options
Preliminary option volume of 24.0M today »

Preliminary option volume…

16:25
11/15/19
11/15
16:25
11/15/19
16:25
Conference/Events
Federal Reserve Bank of San Francisco participates in a discussion »

San Francisco Federal…

GNLN

Greenlane

$3.36

-0.05 (-1.47%)

16:23
11/15/19
11/15
16:23
11/15/19
16:23
Hot Stocks
Greenlane CEO buys 56.4K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJG

Arthur J. Gallagher

$91.89

-0.42 (-0.45%)

16:20
11/15/19
11/15
16:20
11/15/19
16:20
Syndicate
Breaking Syndicate news story on Arthur J. Gallagher »

Arthur J. Gallagher files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.